Skip to main content
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 7/2017

01.07.2017 | Reports of Original Investigations

Effect of magnesium sulfate on oxytocin-induced contractility in human myometrium: an in vitro study

verfasst von: Desire N. Onwochei, MBBS, BSc (Hons), Jose C. A. Carvalho, MD, PhD, Alice Luca, MSc, John Kingdom, MD, Mrinalini Balki, MD

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to determine the contractile patterns induced by oxytocin in myometrium exposed to magnesium sulfate (MgSO4). We hypothesized that MgSO4 pretreatment would reduce oxytocin-induced myometrial contractions in both oxytocin-naïve and oxytocin-desensitized myometrium.

Methods

In this prospective in vitro study, myometrial samples were obtained from 26 women undergoing elective Cesarean deliveries. Samples were divided into six groups. Four groups were apportioned to no pretreatment (control group), oxytocin 10−5 M pretreatment (desensitization group), MgSO4 3.5 mM pretreatment, and MgSO4 3.5 mM + oxytocin 10−5M pretreatment. This was followed by dose-response testing to oxytocin 10−10 to 10−5M in all four groups. Two additional groups included MgSO4 3.5 mM pretreatment and MgSO4 3.5 mM + oxytocin 10−5 M pretreatment, followed by dose-response testing to oxytocin along with MgSO4 3.5 mM. The outcomes were motility index (MI), as defined by the amplitude (g) × frequency of myometrial contractions (c) over ten minutes, and area under the curve (AUC).

Results

In oxytocin-naïve myometrium, the mean (standard error [SE]) MI was not affected by MgSO4 pretreatment [3.31 (0.20) √g⋅c/10 min] as compared with control (P = 0.88), even when MgSO4 was continued during dose-response testing [2.50 (0.19) √g⋅c/10 min; P = 0.41]. In the oxytocin-desensitized model, mean (SE) MI was not affected by MgSO4 pretreatment [2.60 (0.21) √g⋅c/10 min; P = 0.68], but when MgSO4 was continued during the dose-response period, the MI was significantly reduced compared with control [1.89 (0.13) √g⋅c/10 min; P < 0.001]. The results for AUC were similar to MI, except for a significant reduction in oxytocin-naïve myometrium when MgSO4 was continued during dose-response testing (P = 0.02).

Conclusion

Magnesium sulfate pretreatment does not impair oxytocin-induced myometrial contractility in oxytocin-naïve or desensitized myometrium unless it is continued during oxytocin dose-response testing. These results suggest that its tocolytic effect is likely dependent on an extracellular mechanism. The study was registered with ClinicalTrials.gov, number NCT02647268.
Literatur
1.
Zurück zum Zitat Elliott JP, Lewis DF, Morrison JC, Garite TJ. In defense of magnesium sulfate. Obstet Gynecol 2009; 113: 1341-8.CrossRefPubMed Elliott JP, Lewis DF, Morrison JC, Garite TJ. In defense of magnesium sulfate. Obstet Gynecol 2009; 113: 1341-8.CrossRefPubMed
2.
Zurück zum Zitat Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226.CrossRefPubMedPubMedCentral Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Crowther CA, Brown J, McKinlay CJ, Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014; 8: CD001060. Crowther CA, Brown J, McKinlay CJ, Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014; 8: CD001060.
4.
Zurück zum Zitat Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669-76.CrossRefPubMed Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669-76.CrossRefPubMed
5.
Zurück zum Zitat Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol 2009; 114: 669-73.CrossRefPubMed Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol 2009; 114: 669-73.CrossRefPubMed
6.
Zurück zum Zitat Doyle L, Crowther C, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; 1: CD004661. Doyle L, Crowther C, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; 1: CD004661.
7.
Zurück zum Zitat Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.CrossRefPubMed Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.CrossRefPubMed
8.
Zurück zum Zitat Magee LA, Pels A, Helewa M, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36: 416-41. Magee LA, Pels A, Helewa M, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36: 416-41.
9.
Zurück zum Zitat von Schmidt auf Altenstadt JF, Hukkelhoven CW, van Roosmalen J, Bloemenkamp KW. Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in the Netherlands. PLoS One 2013; 8: e81959. von Schmidt auf Altenstadt JF, Hukkelhoven CW, van Roosmalen J, Bloemenkamp KW. Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in the Netherlands. PLoS One 2013; 8: e81959.
10.
Zurück zum Zitat Szal SE, Croughan-Minihane MS, Kilpatrick SJ. Effect of magnesium prophylaxis and preeclampsia on the duration of labor. Am J Obstet Gynecol 1999; 180: 1475-9.CrossRefPubMed Szal SE, Croughan-Minihane MS, Kilpatrick SJ. Effect of magnesium prophylaxis and preeclampsia on the duration of labor. Am J Obstet Gynecol 1999; 180: 1475-9.CrossRefPubMed
11.
Zurück zum Zitat Graham NM, Gimovsky AC, Roman A, Berghella V. Blood loss at cesarean delivery in women on magnesium sulfate for preeclampsia. J Matern Fetal Neonatal Med 2016; 29: 1817-21.PubMed Graham NM, Gimovsky AC, Roman A, Berghella V. Blood loss at cesarean delivery in women on magnesium sulfate for preeclampsia. J Matern Fetal Neonatal Med 2016; 29: 1817-21.PubMed
12.
Zurück zum Zitat Phaneuf S, Asbóth G, Carrasco MP, et al. Desensitization of oxytocin receptors in human myometrium. Hum Reprod Update 1998; 4: 625-33.CrossRefPubMed Phaneuf S, Asbóth G, Carrasco MP, et al. Desensitization of oxytocin receptors in human myometrium. Hum Reprod Update 1998; 4: 625-33.CrossRefPubMed
13.
Zurück zum Zitat Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol 2003; 188: 497-502.CrossRefPubMed Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol 2003; 188: 497-502.CrossRefPubMed
14.
Zurück zum Zitat Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Oxytocin pretreatment attenuates oxytocin-induced contractions in human myometrium in vitro. Anesthesiology 2013; 119: 552-61.CrossRefPubMed Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Oxytocin pretreatment attenuates oxytocin-induced contractions in human myometrium in vitro. Anesthesiology 2013; 119: 552-61.CrossRefPubMed
15.
Zurück zum Zitat Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006; 107: 45-50.CrossRefPubMed Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006; 107: 45-50.CrossRefPubMed
16.
Zurück zum Zitat Frey HA, Tuuli MG, England SK, et al. Factors associated with higher oxytocin requirements in labor. J Matern Fetal Neonatal Med 2015; 28: 1614-9.CrossRefPubMed Frey HA, Tuuli MG, England SK, et al. Factors associated with higher oxytocin requirements in labor. J Matern Fetal Neonatal Med 2015; 28: 1614-9.CrossRefPubMed
17.
Zurück zum Zitat Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1997; 176: 623-7.CrossRefPubMed Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1997; 176: 623-7.CrossRefPubMed
18.
Zurück zum Zitat Magalhaes JK, Carvalho JC, Parkes RK, Kingdom J, Li Y, Balki M. Oxytocin pretreatment decreases oxytocin-induced myometrial contractions in pregnant rats in a concentration-dependent but not time-dependent manner. Reprod Sci 2009; 16: 501-8.CrossRefPubMed Magalhaes JK, Carvalho JC, Parkes RK, Kingdom J, Li Y, Balki M. Oxytocin pretreatment decreases oxytocin-induced myometrial contractions in pregnant rats in a concentration-dependent but not time-dependent manner. Reprod Sci 2009; 16: 501-8.CrossRefPubMed
19.
Zurück zum Zitat Balki M, Cristian AL, Kingdom J, Carvalho JC. Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha. Reprod Sci 2010; 17: 269-77.CrossRefPubMed Balki M, Cristian AL, Kingdom J, Carvalho JC. Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha. Reprod Sci 2010; 17: 269-77.CrossRefPubMed
20.
Zurück zum Zitat Balki M, Kanwal N, Erik-Soussi M, Kingdom J, Carvalho JC. Contractile efficacy of various prostaglandins in pregnant rat myometrium pretreated with oxytocin. Reprod Sci 2012; 19: 968-75.CrossRefPubMed Balki M, Kanwal N, Erik-Soussi M, Kingdom J, Carvalho JC. Contractile efficacy of various prostaglandins in pregnant rat myometrium pretreated with oxytocin. Reprod Sci 2012; 19: 968-75.CrossRefPubMed
21.
Zurück zum Zitat Caldeyro-Barcia R, Sica-Blanco Y, Poseiro JJ, et al. A quantitative study of the action of synthetic oxytocin on the pregnant human uterus. J Pharmacol Exp Ther 1957; 121: 18-31.PubMed Caldeyro-Barcia R, Sica-Blanco Y, Poseiro JJ, et al. A quantitative study of the action of synthetic oxytocin on the pregnant human uterus. J Pharmacol Exp Ther 1957; 121: 18-31.PubMed
22.
Zurück zum Zitat Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women. Can J Anesth 2014; 61: 808-18.CrossRefPubMed Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women. Can J Anesth 2014; 61: 808-18.CrossRefPubMed
23.
Zurück zum Zitat Burton MJ, Dziuk HE, Fahning ML, Zemjanis R. Myometrial activity during natural and dexamethasone-induced parturition in the cow. Am J Vet Res 1987; 48: 37-44.PubMed Burton MJ, Dziuk HE, Fahning ML, Zemjanis R. Myometrial activity during natural and dexamethasone-induced parturition in the cow. Am J Vet Res 1987; 48: 37-44.PubMed
25.
Zurück zum Zitat Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81: 629-83.PubMed Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81: 629-83.PubMed
26.
Zurück zum Zitat Pritchard JA. The use of magnesium sulfate in preeclampsia-eclampsia. J Reprod Med 1979; 23: 107-14.PubMed Pritchard JA. The use of magnesium sulfate in preeclampsia-eclampsia. J Reprod Med 1979; 23: 107-14.PubMed
27.
Zurück zum Zitat Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000; 38: 305-14.CrossRefPubMed Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000; 38: 305-14.CrossRefPubMed
28.
Zurück zum Zitat Bloss JD, Hankins GD, Hauth JC, Gilstrap LC 3rd. The effect of oxytocin infusion on the pharmacokinetics of intramuscular magnesium sulfate therapy. Am J Obstet Gynecol 1987; 157: 156-60.CrossRefPubMed Bloss JD, Hankins GD, Hauth JC, Gilstrap LC 3rd. The effect of oxytocin infusion on the pharmacokinetics of intramuscular magnesium sulfate therapy. Am J Obstet Gynecol 1987; 157: 156-60.CrossRefPubMed
29.
Zurück zum Zitat Yildirim E, Macun HC, Cinar M, et al. The effects of magnesium sulphate on the contractile activity of uterus in an animal model of preeclampsia. Clin Exp Obstet Gynecol 2014; 41: 169-73.PubMed Yildirim E, Macun HC, Cinar M, et al. The effects of magnesium sulphate on the contractile activity of uterus in an animal model of preeclampsia. Clin Exp Obstet Gynecol 2014; 41: 169-73.PubMed
30.
Zurück zum Zitat Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW. Effect of magnesium sulfate on contractile force and intracellular calcium concentration in pregnant human myometrium. Am J Obstet Gynecol 2006; 194: 1384-90.CrossRefPubMed Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW. Effect of magnesium sulfate on contractile force and intracellular calcium concentration in pregnant human myometrium. Am J Obstet Gynecol 2006; 194: 1384-90.CrossRefPubMed
31.
Zurück zum Zitat Tang YY, Du Y, Ni J, Ma YS, Lin XM, Zhou J. Relaxant effects of metoclopramide and magnesium sulfate on isolated pregnant myometrium: an in vitro study. Int J Obstet Anesth 2014; 23: 131-7.CrossRefPubMed Tang YY, Du Y, Ni J, Ma YS, Lin XM, Zhou J. Relaxant effects of metoclopramide and magnesium sulfate on isolated pregnant myometrium: an in vitro study. Int J Obstet Anesth 2014; 23: 131-7.CrossRefPubMed
Metadaten
Titel
Effect of magnesium sulfate on oxytocin-induced contractility in human myometrium: an in vitro study
verfasst von
Desire N. Onwochei, MBBS, BSc (Hons)
Jose C. A. Carvalho, MD, PhD
Alice Luca, MSc
John Kingdom, MD
Mrinalini Balki, MD
Publikationsdatum
01.07.2017
Verlag
Springer US
Erschienen in
Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 7/2017
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI
https://doi.org/10.1007/s12630-017-0867-3

Weitere Artikel der Ausgabe 7/2017

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 7/2017 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.